文献速递浆细胞疾病造血干细胞移植与细胞治疗

SeaLAND III期试验:塞利尼索联合来那度胺对比单用来那度胺作为新诊断多发性骨髓瘤自体移植后维持治疗

Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial.
PubMed 文献 · Br J Haematol · 2026-09-22

SeaLAND(ALLG MM23)是一项随机、开放标签III期研究,评估低剂量每周塞利尼索(40 mg)联合来那度胺对比单用来那度胺作为新诊断、适合移植的多发性骨髓瘤患者自体移植后维持治疗。共入组142例患者(来那度胺组64例,联合组78例),因无效提前终止。联合组最佳缓解≥CR率数值上较高但无统计学差异(67% vs 53%,p=0.09)。中位随访24个月,无进展生存期(PFS)无显著差异(HR=1.22;95%CI 0.62-2.41;p=0.56),24个月PFS率分别为来那度胺组73%(95%CI 57%-84%)和联合组70%(95%CI 56%-81%)。联合组来那度胺平均相对剂量强度(RDI)较低(68% vs 81%,p=0.002),塞利尼索平均RDI为55%。联合组≥3级不良事件更常见(85% vs 45%,p<0.001),常见严重非血液学不良事件包括感染(来那度胺组6%,联合组19%,p<0.01)和胃肠道疾病(来那度胺组3%,联合组14%,p<0.05)。塞利尼索联合来那度胺维持治疗未改善PFS且显著增加毒性,不能推荐用于一般骨髓瘤人群;在高危疾病中未观察到获益。

要点

  • 塞利尼索联合来那度胺维持治疗未改善PFS,因无效提前终止。
  • 联合组≥3级不良事件更常见(85% vs 45%),感染和胃肠道事件增加。
  • 联合组来那度胺平均RDI较低(68% vs 81%),塞利尼索平均RDI为55%。

核心结论

  • 塞利尼索联合来那度胺维持治疗未改善PFS且显著增加毒性,不能推荐用于一般骨髓瘤人群;在高危疾病中未观察到获益。

研究设计与样本

  • 随机、开放标签III期研究(SeaLAND,ALLG MM23),评估低剂量每周塞利尼索(40 mg)联合来那度胺对比单用来那度胺作为新诊断、适合移植的多发性骨髓瘤患者自体移植后维持治疗,共入组142例患者(来那度胺组64例,联合组78例),因无效提前终止。

主要发现

  • 最佳缓解≥CR率联合组67% vs 来那度胺组53%(p=0.09)。
  • 中位随访24个月,PFS无显著差异(HR=1.22;95%CI 0.62-2.41;p=0.56)。
  • 24个月PFS率来那度胺组73%(95%CI 57%-84%),联合组70%(95%CI 56%-81%)。
  • 联合组来那度胺平均RDI较低(68% vs 81%,p=0.002),塞利尼索平均RDI为55%。
  • 联合组≥3级不良事件更常见(85% vs 45%,p<0.001),感染(6% vs 19%,p<0.01)和胃肠道疾病(3% vs 14%,p<0.05)增加。

临床怎么用

  • 不推荐塞利尼索联合来那度胺作为一般骨髓瘤人群的自体移植后维持治疗。

局限性

  • 研究因无效提前终止,样本量有限(共142例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SeaLAND (ALLG MM23, ACTRN12620000291987) was a randomized, open-label phase III study evaluating low-dose weekly selinexor (40 mg) plus lenalidomide (selinexor-R) versus lenalidomide alone (R) as post-transplant maintenance therapy for newly diagnosed, transplant-eligible multiple myeloma. A total of 142 patients were enrolled (R = 64; selinexor-R = 78); the trial closed early for futility. At best response, the complete response (≥CR) rate was numerically, but not significantly, higher with selinexor-R than R (67% vs. 53%, p = 0.09). At 24 months median follow-up, progression-free survival (PFS) was not significantly different between selinexor-R compared to R (hazard ratio [HR] = 1.22; 95% confidence interval [CI] 0.62-2.41; p = 0.56); 24-month PFS rates were 73% (95% CI 57%-84%) for R and 70% (95% CI: 56%-81%) for selinexor-R. The mean relative dose intensity (RDI) of R was lower in the selinexor-R arm compared to R alone (68% vs. 81%, p = 0.002); the mean RDI of S was 55%. Grade ≥3 adverse events were more frequent with selinexor-R (85% vs. 45%, p < 0.001). Common severe non-haematological adverse events included infections (R: 6%, selinexor-R: 19%, p < 0.01) and gastrointestinal disorders (R: 3%, selinexor-R: 14%, p < 0.05). Selinexor-R maintenance did not improve PFS and substantially increased toxicity. Selinexor-R maintenance cannot be recommended for the general myeloma population; we did not observe a benefit among high-risk disease.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rees MJ, Lasica M, Kalff A, et al. Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial. Br J Haematol. 2026. PMID: 42770812. doi:10.1111/bjh.70851

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。